Source: Gene Online, June 2025
A recent study presented at the ASCO 2025 conference examined the efficacy of combining nivolumab and relatlimab in patients with resected stage 3 or stage 4 melanoma. Researchers found that the combination therapy did not lead to a significant improvement in recurrence-free survival for these patients.
The investigation focused on whether the dual immunotherapy approach could provide better outcomes compared to existing treatments for individuals who had undergone surgical removal of advanced melanoma.